No information available. |
Summary of Clinical Use ![]() |
Xilonix is being evaluated in Phase 3 clinical trial as a novel therapy for colorectal cancer, and Phase 1 for non-small cell lung cancer (NSCLC). |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
The rationale for using anti-IL-1α antibodies to treat cancer is provided in patent US20100040574 [2]. |